SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left ventricular (LV) dysfunction. These findings were presented at the San Antonio Breast Cancer Symposium.1
by Joyce Pagan
Oncology Nurse Advisor
December 09, 2015
